MBX Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
MBX Biosciences, Inc. (MBX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-12
- MBX Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 0.00%.
- MBX Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 0.00%.
- MBX Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -0.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-12 | |
| 2024-12-31 | 0.00% 10-K · filed 2026-03-12 | -0.60% 10-K · filed 2025-03-17 |
| 2023-12-31 | -0.80% 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |